Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 6.68
AGEN's Cash to Debt is ranked higher than
67% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. AGEN: 6.68 )
AGEN' s 10-Year Cash to Debt Range
Min: 0.24   Max: 106.58
Current: 6.68

0.24
106.58
Equity to Asset 0.31
AGEN's Equity to Asset is ranked higher than
57% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. AGEN: 0.31 )
AGEN' s 10-Year Equity to Asset Range
Min: -1.33   Max: 0.92
Current: 0.31

-1.33
0.92
F-Score: 5
Z-Score: -10.19
M-Score: -1.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -616.91
AGEN's Operating margin (%) is ranked higher than
61% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. AGEN: -616.91 )
AGEN' s 10-Year Operating margin (%) Range
Min: -11732.38   Max: -42.23
Current: -616.91

-11732.38
-42.23
Net-margin (%) -604.94
AGEN's Net-margin (%) is ranked higher than
61% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. AGEN: -604.94 )
AGEN' s 10-Year Net-margin (%) Range
Min: -11762.54   Max: -70.95
Current: -604.94

-11762.54
-70.95
ROE (%) -112.06
AGEN's ROE (%) is ranked higher than
57% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. AGEN: -112.06 )
AGEN' s 10-Year ROE (%) Range
Min: -715.3   Max: -53.06
Current: -112.06

-715.3
-53.06
ROA (%) -52.04
AGEN's ROA (%) is ranked higher than
63% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. AGEN: -52.04 )
AGEN' s 10-Year ROA (%) Range
Min: -94.08   Max: -41.12
Current: -52.04

-94.08
-41.12
ROC (Joel Greenblatt) (%) -948.52
AGEN's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. AGEN: -948.52 )
AGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -986.59   Max: -199.94
Current: -948.52

-986.59
-199.94
Revenue Growth (3Y)(%) -5.00
AGEN's Revenue Growth (3Y)(%) is ranked higher than
74% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. AGEN: -5.00 )
AGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -54.7   Max: 100
Current: -5

-54.7
100
EBITDA Growth (3Y)(%) -7.70
AGEN's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. AGEN: -7.70 )
AGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -51   Max: 17
Current: -7.7

-51
17
EPS Growth (3Y)(%) -16.30
AGEN's EPS Growth (3Y)(%) is ranked higher than
71% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. AGEN: -16.30 )
AGEN' s 10-Year EPS Growth (3Y)(%) Range
Min: -40   Max: 19.4
Current: -16.3

-40
19.4
» AGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AGEN Guru Trades in Q1 2014

George Soros 102,200 sh (New)
Jean-Marie Eveillard 200,000 sh (New)
Robert Bruce 233,515 sh (unchged)
Paul Tudor Jones 17,411 sh (-37.82%)
» More
Q2 2014

AGEN Guru Trades in Q2 2014

Robert Bruce 233,515 sh (unchged)
George Soros Sold Out
Jean-Marie Eveillard Sold Out
Paul Tudor Jones 16,999 sh (-2.37%)
» More
Q3 2014

AGEN Guru Trades in Q3 2014

Robert Bruce 233,515 sh (unchged)
Paul Tudor Jones 11,197 sh (-34.13%)
» More
Q4 2014

AGEN Guru Trades in Q4 2014

Paul Tudor Jones 15,497 sh (+38.40%)
Robert Bruce 233,515 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Agenus Inc

Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine
Disclosure: We neither own AGEN nor have any financial relationship with the company. Read more...

Ratios

vs
industry
vs
history
P/B 14.20
AGEN's P/B is ranked higher than
53% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. AGEN: 14.20 )
AGEN' s 10-Year P/B Range
Min: 2.5   Max: 37.35
Current: 14.2

2.5
37.35
P/S 45.10
AGEN's P/S is ranked higher than
61% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. AGEN: 45.10 )
AGEN' s 10-Year P/S Range
Min: 4.61   Max: 662.4
Current: 45.1

4.61
662.4
EV-to-EBIT -7.24
AGEN's EV-to-EBIT is ranked higher than
64% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AGEN: -7.24 )
AGEN' s 10-Year EV-to-EBIT Range
Min: -26.1   Max: -1.2
Current: -7.24

-26.1
-1.2
Current Ratio 4.62
AGEN's Current Ratio is ranked higher than
74% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. AGEN: 4.62 )
AGEN' s 10-Year Current Ratio Range
Min: 2.48   Max: 21.68
Current: 4.62

2.48
21.68
Quick Ratio 4.61
AGEN's Quick Ratio is ranked higher than
75% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. AGEN: 4.61 )
AGEN' s 10-Year Quick Ratio Range
Min: 2.42   Max: 21.68
Current: 4.61

2.42
21.68
Days Inventory 3.00
AGEN's Days Inventory is ranked higher than
98% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AGEN: 3.00 )
AGEN' s 10-Year Days Inventory Range
Min: 5.45   Max: 37996.5
Current: 3

5.45
37996.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.70
AGEN's Price/Median PS Value is ranked higher than
78% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. AGEN: 1.70 )
AGEN' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 119.37
Current: 1.7

0.2
119.37
Earnings Yield (Greenblatt) -12.80
AGEN's Earnings Yield (Greenblatt) is ranked higher than
55% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. AGEN: -12.80 )
AGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.5   Max: 0
Current: -12.8

-14.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AJ81.Germany,
Agenus Inc formerly known as Antigenics Inc was incorporated in 1994. The Company, along with its subsidiaries, is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators, heat shock protein vaccines and adjuvants. It is focused on immunotherapeutic products based on core platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Its core technology portfolio consists of Heat Shock Protein Platform, and Saponin Platform. Within HSP Platform the Company is developing its Prophage Series cancer vaccines and Recombinant Series. In Prophage Series the Company has tested product candidates in Phase 3 clinical trials for the treatment of renal cell carcinoma, the common type of kidney cancer, and for metastatic melanoma, as well as in Phase 1 and Phase 2 clinical trials. In addition, the Cancer Therapy Evaluation Program of the National Cancer Institute opened patient enrollment in 2013 for a 222-patient, multi-center, randomized Phase 2 trial of Prophage Series vaccine G-200 in combination with Avastin in patients with surgically resectable recurrent glioma. HerpV, a therapeutic vaccine candidate from the Recombinant Series which contains QS-21 Stimulon, has been tested in a Phase 1 clinical trial for the treatment of genital herpes and is now in a Phase 2 trial. Within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by licensees in numerous vaccines under development in trials, some as advanced as Phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus, and tuberculosis. The Company's business activities include product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of its collaborations. The Company faces intense competition from pharmaceutical companies and specialized biotechnology companies that market products or that are engaged in the development of product candidates directed at cancer, infectious diseases and degenerative disorders. Several of these companies have products that utilize similar technologies and patient-specific medicine techniques. The Company is also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act and the Resource Conservation and Recovery Act, and other current and potential future federal, state, or local regulations.
» More Articles for AGEN

Headlines

Articles On GuruFocus.com
rusty Jan 26 2015 
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
Agenus: Grossly Undervalued GlaxoSmithKline Acquisition Target Sep 11 2012 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 

More From Other Websites
Lightning Round: Be careful-this lurks everywhere Apr 01 2015
Agenus draws vote of confidence Mar 30 2015
Agenus Boosted by Big Pharma Deals Mar 24 2015
AGENUS INC Financials Mar 21 2015
AGENUS INC Files SEC form 10-K, Annual Report Mar 16 2015
Agenus reports 4Q loss Feb 26 2015
Agenus reports 4Q loss Feb 26 2015
Agenus (AGEN) Reports Wider-than-Expected Q4 Loss - Tale of the Tape Feb 26 2015
Q3 2014 Agenus Inc Earnings Release - Before Market Open Feb 26 2015
AGENUS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an... Feb 26 2015
Agenus Reports Fourth Quarter and Full Year 2014 Financial Results Feb 26 2015
Agenus to Present at the Cowen and Company 35th Annual Health Care Conference Feb 25 2015
Agenus to Report Fourth Quarter and Year End 2014 Financial Results on February 26, 2015; Conference... Feb 20 2015
AGENUS INC Files SEC form 8-K, Other Events Feb 19 2015
Agenus to Present at the 17th Annual BIO CEO & Investor Conference Feb 03 2015
Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics Jan 23 2015
Agenus (AGEN) Shares March Higher, Can It Continue? - Tale of the Tape Jan 16 2015
The Zacks Analyst Blog Highlights: NPS Pharmaceuticals, Celgene, Pharmacyclics, Agenus and Incyte -... Jan 15 2015
AstraZeneca Inks Immuno-Oncology Agreement with Omnis - Analyst Blog Jan 14 2015
Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst... Jan 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK